CytRx Completes Sale of Molecular Chaperone Assets to Orphazyme ApS in Deal Worth up to $120 Million

CytRx has sold its portfolio of molecular chaperone drugs, including arimocomol which is currently in clinical development for ALS, to Danish biotech Orphazyme. While CytRx will concentrate on its oncology program, Orphazyme will develop theacquired molecular chaperone therapies for the treatment of lysosomal storage diseases.

Click here to read more.

Share this: